156 related articles for article (PubMed ID: 35698011)
1. Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
Chen H; Lu Y; Shi S; Zhang Q; Cao X; Sun L; An D; Zhang X; Kong X; Liu J
Pharm Res; 2022 Aug; 39(8):1891-1906. PubMed ID: 35698011
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
3. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM
Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480
[TBL] [Abstract][Full Text] [Related]
4. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
[TBL] [Abstract][Full Text] [Related]
5. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
6. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
7. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
Miyasaka K
Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
[TBL] [Abstract][Full Text] [Related]
8. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
Paquot N
Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
10. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
11. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
12. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
13. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
14. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Jordy AB; Albayaty M; Breitschaft A; Anderson TW; Christiansen E; Houshmand-Øregaard A; Manigandan E; Bækdal TA
Clin Pharmacokinet; 2021 Sep; 60(9):1171-1185. PubMed ID: 33782832
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
[TBL] [Abstract][Full Text] [Related]
16. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Bækdal TA; Borregaard J; Hansen CW; Thomsen M; Anderson TW
Clin Pharmacokinet; 2019 Sep; 58(9):1193-1203. PubMed ID: 30945118
[TBL] [Abstract][Full Text] [Related]
17. Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu S; Mellbin L; Kaiser M; Khunti K
Prim Care Diabetes; 2021 Feb; 15(1):59-68. PubMed ID: 32826189
[TBL] [Abstract][Full Text] [Related]
18. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.
Mosenzon O; Miller EM; Warren ML
Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439
[TBL] [Abstract][Full Text] [Related]
19. Safety of injectable semaglutide for type 2 diabetes.
Peter R; Bain SC
Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
Lovshin JA
Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
